|
|
 |
February 12, 2008 |
Now Available:
Download the podcast of Dr. Gaylis's video presentation
CME Opportunity:
International Society of Extremity MRI in Rheumatology Conference:
Chicago, April 10, 2008
Musculoskeletal Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.
With biweekly and special edition newsletters, MSK Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
Consumer News: Learn what your patients are reading in the popular press
Chronic Pain Harms Brain's Wiring
Patients with chronic low back pain experience a constant firing of neurons in the front region of the cortex, which could cause permanent damage...
New from PubMed: Keep up-to-date with what is on PubMed
Nabilone for the Treatment of Pain in Fibromyalgia
Nabilone, a synthetic cannabinoid, relieves pain and improves symptoms in patients with fibromyalgia...
MSK Video Report:
Adopting Imaging in RA Management and Rheumatology Practice
Dr. Norman Gaylis discusses the role of imaging in diagnosing and treating RA...
AAD 2008: Phase III Data Look Good for Ustekinumab (CNTO 1275) in Plaque Psoraisis
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23, may hold advantages over existing systemic therapies for chronic plaque psoriasis in terms of its convenience and potentially its safety...
AAD 2008: TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Autoimmunity: Half of RA Patients in Europe Forced to Retire Early; Increasing Healthcare Costs
As many as half of all rheumatoid arthritis (RA) patients are forced into early retirement and must apply for disability within 10 years of disease onset; adding to the extremely high societal and economic costs of RA...
BioPharm Business: UCB Reports US FDA to Review Cimzia License Application for Treatment of RA
UCB announced that the US FDA agreed to accept a Biologics License Application for Cimzia (certolizumab pegol), a PEGylated and Fc-free anti-TNFα antibody-fragment therapeutic, for the treatment of adult patients with active rheumatoid arthritis (RA)...